Morphic Holding Current Ratio 2019-2021 | MORF

Morphic Holding current ratio from 2019 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Morphic Holding Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.44B $0.04B 12.51
2021-03-31 $0.46B $0.03B 13.41
2020-12-31 $0.24B $0.04B 6.07
2020-09-30 $0.22B $0.04B 6.14
2020-06-30 $0.21B $0.05B 4.61
2020-03-31 $0.23B $0.04B 6.12
2019-12-31 $0.24B $0.04B 6.89
2019-09-30 $0.26B $0.03B 9.71
2019-06-30 $0.17B $0.04B 3.97
2019-03-31 $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.144B $0.045B
Morphic Holding Inc. is a biopharmaceutical company. It focuses on the discovery and development of oral small-molecule integrin therapeutics for autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer. Morphic Holding Inc. is based in Waltham, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86